TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s Lymphoma (NHL), and Multiple Sclerosis (MS).
+ 1 more risk
Slightly overvalued with limited growth.
Share Price & News
How has TG Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NKB2's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NKB2 exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: NKB2 exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is TG Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is TG Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NKB2 (€14.5) is trading below our estimate of fair value (€71.05)
Significantly Below Fair Value: NKB2 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NKB2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: NKB2 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NKB2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NKB2 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is TG Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NKB2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NKB2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NKB2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NKB2's revenue (56.5% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: NKB2's revenue (56.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NKB2's Return on Equity is forecast to be high in 3 years time
How has TG Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NKB2 is currently unprofitable.
Growing Profit Margin: NKB2 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NKB2 is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.
Accelerating Growth: Unable to compare NKB2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKB2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: NKB2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is TG Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: NKB2 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NKB2 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NKB2 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NKB2's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: NKB2 has a low level of unsold assets or inventory.
Debt Coverage by Assets: NKB2 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NKB2 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NKB2 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -33% each year
What is TG Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate NKB2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NKB2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NKB2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NKB2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NKB2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Weiss (53yo)
Mr. Michael S. Weiss, also known as Mike, Esq., J.D. has been an Executive Chairman of Mustang Bio Inc. since January 2017 and served as the Interim President and Chief Executive Officer at Mustang Bio Inc ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD1.51M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
|CFO, Corporate Secretary & Treasurer||8.2yrs||US$1.08m||0.39% $5.7m|
|Executive Chairman||8.2yrs||US$9.93m||8.12% $118.1m|
|VP of Investor Relations & Senior VP of Corporate Communications||0yrs||no data||no data|
|Chief Commercial Officer||1.7yrs||no data||no data|
Experienced Management: NKB2's management team is seasoned and experienced (8.2 years average tenure).
|Executive Chairman||8.2yrs||US$9.93m||8.12% $118.1m|
|Independent Director||7.8yrs||US$221.91k||0.10% $1.5m|
|Independent Director||7.8yrs||US$237.32k||0.15% $2.2m|
|Independent Director||5.2yrs||US$227.32k||0.15% $2.1m|
|Independent Director||7.3yrs||US$221.91k||0.15% $2.1m|
|Independent Director||4.7yrs||US$221.91k||0.12% $1.8m|
Experienced Board: NKB2's board of directors are considered experienced (7.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.1%.
TG Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: TG Therapeutics, Inc.
- Ticker: NKB2
- Exchange: DB
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.569b
- Listing Market Cap: US$1.454b
- Shares outstanding: 98.10m
- Website: https://www.tgtherapeutics.com
Number of Employees
- TG Therapeutics, Inc.
- 2 Gansevoort Street
- 9th Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TGTX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Dec 2011|
|NKB2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2011|
|0VGI||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Dec 2011|
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton’s Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 22:14|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.